Enterprise Value

134.3M

Cash

209M

Avg Qtr Burn

-23.17M

Short % of Float

3.82%

Insider Ownership

9.63%

Institutional Own.

28.02%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COMP360 Details
Treatment Resistant Depression

Phase 3

Data readout

RL-007 Details
Cognitive Dysfunction, Schizophrenia

Phase 2b

Data readout

COMP360 Details
Post-traumatic stress disorder

Phase 2

Data readout

GRX-917 Details
Anxiety Disorders

Phase 2

Update

Ibogaine (DMX-1002) Details
Opioid use disorder

Phase 1/2

Update

VLS-01 Details
Treatment Resistant Depression

Phase 1b

Initiation

Phase 1

Update

PCN-101 (R-Ketamine) Details
Treatment Resistant Depression

Phase 1

Update

PCN-101 Details
Treatment Resistant Depression

Failed

Discontinued